New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 8, 2014
10:28 EDTTFM, HOS, VRTX, KPTI, EBKDY, VSTM, ZINC, ZBRA, BECN, BRKROn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: Beacon Roofing (BECN) downgraded to Market Perform from Outperform at William Blair... Bruker (BRKR) downgraded to Neutral from Buy at ISI Group... Erste Group Bank (EBKDY) downgraded to Hold from Buy at Deutsche Bank... Hornbeck Offshore (HOS) downgraded to Equal Weight from Overweight at Stephens... Horsehead Holding (ZINC) downgraded to Market Perform at FBR Capital... Karyopharm (KPTI) downgraded to Perform from Outperform at Oppenheimer... The Fresh Market (TFM) downgraded to Sell from Neutral at Goldman... Verastem (VSTM) downgraded to Perform from Outperform at Oppenheimer... Vertex (VRTX) downgraded to Perform from Outperform at Oppenheimer... Zebra Technologies (ZBRA) downgraded to In-Line from Outperform at Imperial Capital.
News For BECN;BRKR;EBKDY;HOS;ZINC;KPTI;TFM;VSTM;VRTX;ZBRA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 >>
August 20, 2015
16:19 EDTTFMThe Fresh Market announces $200M stock repurchase program
Subscribe for More Information
16:18 EDTTFMThe Fresh Market cites YTD results, current environment for lowered outlook
Interim CEO Crane concluded, "We believe that our strategic initiatives will better position The Fresh Market to compete long-term. We remain focused on evolving our operating model to provide customers with a unique and differentiated grocery shopping experience, although we expect that it will take time to fully realize the benefits of our efforts. Based on year to date results and the current operating environment, we are lowering our previously issued sales and earnings guidance for fiscal 2015."
16:17 EDTTFMThe Fresh Market lowers FY15 adjusted EPS view to $1.55-$1.65 from $1.85-$1.93
FY15 consensus $1.85. Management's outlook for the 53-week fiscal 2015 is based upon the following expectations: Total net sales growth for the 53-week fiscal 2015 of approximately 5.0%-7.0% compared to the 52-week fiscal 2014 total net sales. Fiscal 2014 included the benefit of sales from the Company's three California stores prior to their closing; Comparable store sales for the first 52 weeks of fiscal 2015 of -1.0% to -2.5%; An effective tax rate of 37.0% to 37.3%; Approximately $95M-$105M in capital expenditures, primarily related to real estate investments; Unit growth of approximately 18 new stores; Remodeling or refreshing 9 to 10 stores; Approximately 8c per diluted share of earnings related to the 53rd week of operations in the fourth quarter of fiscal 2015.
16:17 EDTTFMThe Fresh Market hits a fresh life low after results
Subscribe for More Information
16:15 EDTTFMThe Fresh Market lowers FY15 outlook
Subscribe for More Information
16:14 EDTTFMThe Fresh Market announces $200M stock repurchase program
16:13 EDTTFMThe Fresh Market reports Q2 adjusted EPS 36c, consensus 40c
Subscribe for More Information
14:42 EDTTFMNotable companies reporting after market close
Subscribe for More Information
10:00 EDTTFMOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
08:08 EDTTFMThe Fresh Market downgraded to Underperform at BofA/Merrill
Subscribe for More Information
07:57 EDTZBRAHuron names Debbie Murphy as Chief Marketing Officer
Subscribe for More Information
07:37 EDTTFMThe Fresh Market downgraded to Underperform from Neutral at BofA/Merrill
07:10 EDTTFMThe Fresh Market price target lowered to $30 from $34 at RBC Capital
RBC Capital analyst William Kirk lowered his price target for The Fresh Market to $30 after reducing his comparable store estimate for the quarter to 0.0%. The company is not immune from the decelerating trends reported by peers, Kirk tells investors in a research note. He reiterates an Underperform rating on The Fresh Market.
05:48 EDTVSTMMizuho keeps TESARO, Verastem, OncoMed as top biotech picks
Subscribe for More Information
August 19, 2015
08:53 EDTKPTIConcerns over Karyopharm overdone, says Wedbush
After eight AML patients taking Karyopharm's Sellinexor developed Sepisis versus two in the control arm, Wedbush quotes a doctor as saying that differences in patients' characteristics between the two arms may have contributed to the high rate of Sepsis in those taking Sellinexor,. Wedbush believes that a study of the 60 mg version of the drug, due out in 4Q16, will show that it improves survival and has an acceptable safety profile. Wedbush increased its discount rate on AML to 45% from 30% to account for higher risk from a reduced dose and cut its price target on the name to $39 from $50, mostly due to the postponement of clinical trial results. However, the firm keeps an Outperform rating on the shares.
August 17, 2015
10:09 EDTTFMOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
08:30 EDTTFMThe Fresh Market downgraded on negative comps risk at BMO Capital
Subscribe for More Information
06:54 EDTTFMThe Fresh Market downgraded to Market Perform from Outperform at BMO Capital
Subscribe for More Information
06:22 EDTVRTXPiper's Tenthoff sees select biotech names outperforming in second half
Piper Jaffray analyst Edward Tenthoff expects drug launches, clinical data read-outs and potential partnerships to drive outperformance for select biotech names in the second half of 2015. Despite some recent profit-taking, 2015 has been another strong year for biotech stocks, Tenthoff tells investors in a research note. Names with important second half of the year catalysts include Vertex (VRTX), Regeneron (REGN), Seattle Genetics (SGEN), Exelixis (EXEL), Sarepta (SRPT), Novavax (NVAX), Arrowhead (ARWR), Array BioPharma (ARRY), Alnylam (ALNY), Genocea (GNCA), CymaBay (CBAY), Idera Pharmaceuticals (IDRA), Vitae Pharmaceuticals (VTAE).
August 16, 2015
13:07 EDTBECNBeacon Roofing no longer looks cheap, Barron's says
Subscribe for More Information
1 | 2 | 3 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use